AVITA Medical to Host Investor Webinar Briefing
Rhea-AI Summary
AVITA Medical (NASDAQ:RCEL) will host an investor webinar on May 20, 2026 at 4:00 p.m. PT (May 21, 2026 at 9:00 a.m. AEST), featuring President and CEO Cary Vance and CFO David O’Toole. The event will review recent Q1 2026 earnings results and include a Q&A session.
The company will also hold an in-person armchair investor discussion in Melbourne on May 21, 2026 at 4:00 p.m. AEST, covering its acute wound care platform, portfolio, commercial progress, and 2026 execution priorities. Replays of both events will be available on AVITA Medical’s investor relations website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – RCEL
On the day this news was published, RCEL declined 8.11%, reflecting a notable negative market reaction. Argus tracked a trough of -6.9% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $12M from the company's valuation, bringing the market cap to $133.88M at that time.
Data tracked by StockTitan Argus on the day of publication.
VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial Officer, on May 20, 2026, at 4:00 p.m. Pacific Time (May 21, 2026, at 9:00 a.m. Australian Eastern Standard Time).
The webinar presentation will cover financial and business results from AVITA Medical’s recent first quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are invited to submit their questions via the registration page.
To register for the presentation, please follow this Zoom link:
https://us06web.zoom.us/webinar/register/WN_331aOhhgT3mn94RX0_bEaw
A replay will be available on the AVITA Medical website at: https://ir.avitamedical.com/
Armchair Discussion with Cary Vance in Melbourne, Australia
AVITA Medical also invites investors to an armchair investor discussion at a pivotal point in the Company’s commercialization of its acute wound care platform.
Join Cary Vance, President and Chief Executive Officer, in conversation with Michael Woods, Chief Executive Officer of Newburyport Partners and veteran healthcare investor, for a live discussion and Q&A.
The session will provide an overview of AVITA Medical’s integrated portfolio, commercial progress and execution priorities for 2026.
- Date & Time: 4pm AEST, Thursday 21 May 2026
- Venue: FB Rice — Level 33, 477 Collins St, Melbourne
To register for the Melbourne briefing, please visit: bit.ly/avh0526
A replay will be available on the AVITA Medical website, https://ir.avitamedical.com/, following the event.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix.
In international markets, RECELL is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO® are CE-marked in Europe, have TGA certification in Australia, and Medsafe WAND listing in New Zealand; RECELL is PMDA-approved in Japan.
To learn more, visit www.avitamedical.com.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com
media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
©2026 AVITA Medical. AVITA Medical®, Cohealyx®, RECELL®, RECELL GO®, and Spray-On Skin™ are trademarks of AVITA Medical. PermeaDerm® is a registered trademark owned by Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.
